0.079
0.00 (1.28%)
| Previous Close | 0.078 |
| Open | 0.080 |
| Volume | 256,239 |
| Avg. Volume (3M) | 292,537 |
| Market Cap | 22,404,164 |
| Price / Book | 4.42 |
| 52 Weeks Range | |
| Earnings Date | 21 Feb 2025 |
| Profit Margin | -68.73% |
| Operating Margin (TTM) | 20.71% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 87.30% |
| Total Debt/Equity (MRQ) | 3.25% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -2.12 M |
| Levered Free Cash Flow (TTM) | -2.23 M |
| Return on Assets (TTM) | -33.68% |
| Return on Equity (TTM) | -71.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | RHYTHM BIO FPO [RHY] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -2.5 |
| Average | -1.50 |
|
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 27.93% |
| % Held by Institutions | 6.18% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |